Clinical trial NCT01437397: Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Official title: A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
Chronic Obstructive Pulmonary Disease
Chronic Bronchitis
Emphysema
Airflow Obstruction, Chronic
Chronic Airflow Obstruction
Chronic Obstructive Airway Disease
Chronic Obstructive Lung Disease
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2011-09-20
Enrollment: 1692
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this Phase III study is to assess the maintenance bronchodilator effects of the fixed dose combination versus monotherapies. This study will also assess the effects of the fixed dose combination in terms of COPD symptoms, disease related health status and the long-term safety and tolerability of the fixed dose combination. This study will include a 24 week treatment period, preceding by a run-in period, followed by a two week follow up visit. All patients will be randomized to one of four treatment arms or placebo.


Eligibility criteria: Inclusion Criteria:

* Male or female patients at least 40 years of age
* Current or former cigarette smoker with a cigarette smoking history of at least 10 pack-years
* A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the GOLD guidelines and stable airway obstruction. Patients had to have a postbronchodilator FEV1/FVC ratio \< 70% at Visit 1 (GOLD, 2010)
* Post-albuterol/salbutamol FEV1 values ≥ 30% and \< 80% of predicted value. FEV1 was measured at the Screening Visit (Visit 1) 10 to 15 minutes after inhalation of albuterol/salbutamol. Predicted normal used for calculation purposes were based on National Health and Nutrition Examination Survey III predicted values (Hankinson et al, 1999)
* Able to perform acceptable and repeatable pulmonary function testing for FEV1 according to ATS/ERS criteria (Miller et al, 2005) at Screening Visit (Visit 1) and throughout their participation in the trial
* Negative serum β-human chorionic gonadotropin pregnancy test at Visit 1 and must have been using hormonal contraceptives or a barrier method plus a spermicidal agent; otherwise at least 1-year postmenopausal or surgically sterile, defined as having a hysterectomy or tubal ligation (applied to female patients only)
* Judged by the Principal Investigator to be in otherwise good stable health based on medical history, physical examination, ECGs, and routine laboratory data evaluations
* Patients previously randomized in an aclidinium monotherapy trial were permitted as long as it had been at least 6 months since the completion of their previous trial participation
* Able to understand the study procedures and be willing to participate in the study as indicated by signing the informed consent

Exclusion Criteria:

* Hospitalization for an acute COPD exacerbation within 3 months before Visit 1
* Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1. Patients who developed a respiratory tract infection or COPD exacerbation during the washout or run-in period were discontinued from the study before randomization
* Any clinically significant respiratory conditions other than COPD, including active tuberculosis, history of interstitial lung disease, pulmonary thromboembolic disease, history of α1-antitrypsin deficiency, pulmonary resection, lung volume surgery, or any other thoracic surgery during the past 12 months, history of bronchiectasis secondary to respiratory diseases other than COPD (eg, cystic fibrosis, Kartagener syndrome), post organ transplantation, or expected to require thoracotomy or other lung surgery during the study
* Clinical history suggesting that the patient had asthma as opposed to COPD (Study Physician was to be contacted to discuss eligibility, if necessary)
* Chronic use of oxygen therapy ≥ 15 hours/day
* Body mass index(BMI) ≥ 40 kg/m2
* Patients who intended to start a pulmonary rehabilitation program during the trial were excluded, as well as those who finished or started it within 3 months prior to Screening Visit
* Clinically significant cardiovascular conditions including: myocardial infarction within the previous 6 months; newly diagnosed arrhythmia within the previous 3 months; unstable angina; unstable arrhythmia that had required changes in pharmacological therapy or other intervention within the previous 6 months; the presence of an automated implantable cardioverter-defibrillator; history of thoracic surgery within the past year before screening; hospitalization within the previous 12 months for heart failure of New York Heart Association functional class III (marked limitation of physical activity and only comfortable at rest, less than ordinary activity causes fatigue, palpitation or dyspnea), or class IV (unable to carry out any physical activity without discomfort) (Criteria Committee of the New York Heart Association criteria, 1994)
* Any uncontrolled infection that may have placed the patient at risk resulting from human immunodeficiency virus, active hepatitis and/or patients with diagnosed active tuberculosis
* QTcB \> 470 msec in the resting ECGs performed at Screening (Visit 1), as indicated in the centralized ECG vendor generated report. Patients who were on a stable dose of medication that may prolong the QTc, but had a documented, stable, and normal QTc, could have been considered
* QTcB \> 470 msec in the resting ECGs performed before randomization at Visit 2, as indicated in the paper tracing generated by the Sponsor-provided ECG equipment
* Clinically relevant abnormalities in the results of the clinical laboratory tests, in ECG parameters other than QTc, or in the physical examination or vital signs at Visit 1 except for those related to COPD
* History of drug or alcohol abuse within the previous 5 years
* Any other serious or uncontrolled physical or mental condition/disease that, as judged by the Investigator, could have placed the patient at higher risk derived from his/her participation in the study, could have confounded the results of the study, or would be likely to have prevented the patient from complying with the requirements of the study or completing the study. If there was a history of such disease, but the condition had been stable for more than 1 year and was judged by the Investigator not to interfere with the patient's participation in the study, the patient may have been included, with the documented approval of the Study Physician
* History of hypersensitivity reaction to inhaled anticholinergics, beta-2 agonists, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm) or a history of acute urinary retention, symptomatic benign prostatic hyperplasia, bladder neck obstruction, or narrow-angle glaucoma. (Note: Patients who had well controlled, stable, asymptomatic benign prostatic hyperplasia were not to be excluded)
* Sitting, resting systolic BP ≥ 160 mm Hg and/or diastolic BP ≥ 100 mm Hg at Visit 1 and Visit 2
* Unable to use a multidose dry-powder inhaler or a pressurized metered-dose inhaler
* Treatment with any other investigational product within 30 days (or 6 half-lives, whichever was longer) before Visit 1
* Previous participation in a clinical trial with aclidinium bromide in an FDC therapy
* Pregnant or breastfeeding
* Current diagnosis of cancer (present in the patient) other than basal or squamous cell skin cancer. Patients who had a history of cancer must have been cleared before Visit 1 (Screening) on a case-by-case basis
* Patients who did not maintain regular day/night, waking/sleeping cycles (eg, night shift workers)
* Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication (Appendix III of the protocol, which can be found in Appendix 16.1.1 of this report)
* Patients who were unlikely to be compliant with study requirements (eg, take their medication, complete their electronic diaries, attend clinic at the required times)
* Patients who were employees or relatives of employees of the investigative study center, FRI, Almirall, SA, or Pharmaceutical Product Development (PPD, Inc.)
* Patients who had any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study or supported excluding the patient from the study

Primary outcomes:
measure: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)
timeFrame: Week 24 of treatment
measure: Change From Baseline in Morning Trough Forced Expiratory Volume in One Second (FEV1)
timeFrame: Week 24 of treatment
Secondary outcomes:
measure: Change in Transition Dyspnea Index (TDI) Focal Score
timeFrame: Week 24 of treatment
measure: Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score
timeFrame: Week 24 of treatment
Other outcomes:
Locations:
city: Anniston
country: United States
facility: Forest Investigative Site 1827
state: Alabama
city: Athens
country: United States
facility: Forest Investigative Site 1920
state: Alabama
city: Birmingham
country: United States
facility: Forest Investigative Site 1162
state: Alabama
city: Birmingham
country: United States
facility: Forest Investigative Site 1493
state: Alabama
city: Birmingham
country: United States
facility: Forest Investigative Site 1937
state: Alabama
city: Florence
country: United States
facility: Forest Investigative Site 1893
state: Alabama
city: Gulf Shores
country: United States
facility: Forest Investigative Site 1824
state: Alabama
city: Jasper
country: United States
facility: Forest Investigative Site 2088
state: Alabama
city: Scottsboro
country: United States
facility: Forest Investigative Site 1918
state: Alabama
city: Glendale
country: United States
facility: Forest Investigative Site 0909
state: Arizona
city: Mesa
country: United States
facility: Forest Investigative Site 1958
state: Arizona
city: Phoenix
country: United States
facility: Forest Investigative Site 1379
state: Arizona
city: Anaheim
country: United States
facility: Forest Investigative Site 1822
state: California
city: Buena Park
country: United States
facility: Forest Investigative Site 1483
state: California
city: Fountain Valley
country: United States
facility: Forest Investigative Site 1809
state: California
city: Fresno
country: United States
facility: Forest Investigative Site 1156
state: California
city: Lincoln
country: United States
facility: Forest Investigative Site 1871
state: California
city: Los Angeles
country: United States
facility: Forest Investigative Site 1873
state: California
city: Riverside
country: United States
facility: Forest Investigative Site 2064
state: California
city: Sacramento
country: United States
facility: Forest Investigative Site 1427
state: California
city: Sacramento
country: United States
facility: Forest Investigative Site 1866
state: California
city: San Diego
country: United States
facility: Forest Investigative Site 1125
state: California
city: San Diego
country: United States
facility: Forest Investigative Site 1898
state: California
city: San Diego
country: United States
facility: Forest Investigative Site 2009
state: California
city: Torrance
country: United States
facility: Forest Investigative Site 1374
state: California
city: Tustin
country: United States
facility: Forest Investigative Site 1813
state: California
city: Vista
country: United States
facility: Forest Investigative Site 1883
state: California
city: Golden
country: United States
facility: Forest Investigative Site 1380
state: Colorado
city: Pueblo
country: United States
facility: Forest Investigative Site 1137
state: Colorado
city: Wheat Ridge
country: United States
facility: Forest Investigative Site 1327
state: Colorado
city: Waterbury
country: United States
facility: Forest Investigative Site 1976
state: Connecticut
city: Bay Pines
country: United States
facility: Forest Investigative Site 1821
state: Florida
city: Brandon
country: United States
facility: Forest Investigative Site 1154
state: Florida
city: Brandon
country: United States
facility: Forest Investigative Site 1944
state: Florida
city: Clearwater
country: United States
facility: Forest Investigative Site 1364
state: Florida
city: Clearwater
country: United States
facility: Forest Investigative Site 1152
state: Florida
city: Clearwater
country: United States
facility: Forest Investigative Site 1875
state: Florida
city: DeLand
country: United States
facility: Forest Investigative Site 0670
state: Florida
city: Edgewater
country: United States
facility: Forest Investigative Site 1516
state: Florida
city: Fort Lauderdale
country: United States
facility: Forest Investigative Site 0990
state: Florida
city: Hialeah
country: United States
facility: Forest Investigative Site 1513
state: Florida
city: Hialeah
country: United States
facility: Forest Investigative Site 1854
state: Florida
city: Hollywood
country: United States
facility: Forest Investigative Site 1882
state: Florida
city: Jacksonville
country: United States
facility: Forest Investigative Site 1543
state: Florida
city: Kissimmee
country: United States
facility: Forest Investigative Site 1416
state: Florida
city: Melbourne
country: United States
facility: Forest Investigative Site 1167
state: Florida
city: Miami
country: United States
facility: Forest Investigative Site 1868
state: Florida
city: Miami
country: United States
facility: Forest Investigative Site 1432
state: Florida
city: Miami
country: United States
facility: Forest Investigative Site 1979
state: Florida
city: Naples
country: United States
facility: Forest Investigative Site 1819
state: Florida
city: North Miami Beach
country: United States
facility: Forest Investigative Site 1808
state: Florida
city: Oldsmar
country: United States
facility: Forest Investigative Site 1950
state: Florida
city: Ormond Beach
country: United States
facility: Forest Investigative Site 1145
state: Florida
city: Panama City
country: United States
facility: Forest Investigative Site 1094
state: Florida
city: Pembroke Pines
country: United States
facility: Forest Investigative Site 1803
state: Florida
city: Pensacola
country: United States
facility: Forest Investigative Site 974
state: Florida
city: Saint Petersburg
country: United States
facility: Forest Investigative Site 1876
state: Florida
city: Sarasota
country: United States
facility: Forest Investigative Site 1817
state: Florida
city: St. Cloud
country: United States
facility: Forest Investigative Site 1829
state: Florida
city: St. Petersburg
country: United States
facility: Forest Investigative Site 1874
state: Florida
city: Tamarac
country: United States
facility: Forest Investigative Site 2082
state: Florida
city: Tampa
country: United States
facility: Forest Investigative Site 2053
state: Florida
city: Tampa
country: United States
facility: Forest Investigative Site 2047
state: Florida
city: Winter Park
country: United States
facility: Forest Investigative Site 1185
state: Florida
city: Winter Park
country: United States
facility: Forest Investigative Site 1860
state: Florida
city: Albany
country: United States
facility: Forest Investigative Site 1982
state: Georgia
city: Atlanta
country: United States
facility: Forest Investigative Site 1900
state: Georgia
city: Austell
country: United States
facility: Forest Investigative Site 0987
state: Georgia
city: Canton
country: United States
facility: Forest Investigative Site 1828
state: Georgia
city: Marietta
country: United States
facility: Forest Investigative Site 1830
state: Georgia
city: Woodstock
country: United States
facility: Forest Investigative Site 2089
state: Georgia
city: Coeur d' Alene
country: United States
facility: Forest Investigative Site 0679
state: Idaho
city: Eagle
country: United States
facility: Forest Investigative Site 1858
state: Idaho
city: Normal
country: United States
facility: Forest Investigative Site 1095
state: Illinois
city: Normal
country: United States
facility: Forest Investigative Site 1912
state: Illinois
city: River Forest
country: United States
facility: Forest Investigative Site 2051
state: Illinois
city: Bowling Green
country: United States
facility: Forest Investigative Site 2033
state: Kentucky
city: Fort Mitchell
country: United States
facility: Forest Investigative Site 2085
state: Kentucky
city: Lexington
country: United States
facility: Forest Investigative Site 0539
state: Kentucky
city: Louisville
country: United States
facility: Forest Investigative Site 1478
state: Kentucky
city: Owensboro
country: United States
facility: Forest Investigative Site 1519
state: Kentucky
city: Covington
country: United States
facility: Forest Investigative Site 1811
state: Louisiana
city: New Orleans
country: United States
facility: Forest Investigative Site 1430
state: Louisiana
city: Opelousas
country: United States
facility: Forest Investigative Site 1812
state: Louisiana
city: Bangor
country: United States
facility: Forest Investigative Site 1814
state: Maine
city: Baltimore
country: United States
facility: Forest Investigative Site 1924
state: Maryland
city: Hollywood
country: United States
facility: Forest Investigative Site 1865
state: Maryland
city: Wheaton
country: United States
facility: Forest Investigative Site 1872
state: Maryland
city: Fall River
country: United States
facility: Forest Investigative Site 1570
state: Massachusetts
city: Fall river
country: United States
facility: Forest Investigative Site 1852
state: Massachusetts
city: North Dartmouth
country: United States
facility: Forest Investigative Site 1029
state: Massachusetts
city: North Dartmouth
country: United States
facility: Forest Investigative Site 1431
state: Massachusetts
city: Ann Arbor
country: United States
facility: Forest Investigative Site 1892
state: Michigan
city: Stevensville
country: United States
facility: Forest Investigative Site 1342
state: Michigan
city: Troy
country: United States
facility: Forest Investigative Site 1487
state: Michigan
city: Edina
country: United States
facility: Forest Investigative Site 1128
state: Minnesota
city: Fridley
country: United States
facility: Forest Investigative Site 1527
state: Minnesota
city: Minneapolis
country: United States
facility: Forest Investigative Site 2041
state: Minnesota
city: Minneapolis
country: United States
facility: Forest Investigative Site 1124
state: Minnesota
city: Plymouth
country: United States
facility: Forest Investigative Site 1619
state: Minnesota
city: Rochester
country: United States
facility: Forest Investigative Site 1118
state: Minnesota
city: Olive Branch
country: United States
facility: Forest Investigative Site 1884
state: Mississippi
city: Chesterfield
country: United States
facility: Forest Investigative Site 1587
state: Missouri
city: Kansas City
country: United States
facility: Forest Investigative Site 1602
state: Missouri
city: Springfield
country: United States
facility: Forest Investigative Site 1856
state: Missouri
city: Springfield
country: United States
facility: Forest Investigative Site 1867
state: Missouri
city: St. Charles
country: United States
facility: Forest Investigative Site 2079
state: Missouri
city: St. Louis
country: United States
facility: Forest Investigative Site 1399
state: Missouri
city: St. Louis
country: United States
facility: Forest Investigative Site 1599
state: Missouri
city: Bozeman
country: United States
facility: Forest Investigative Site 1831
state: Montana
city: Missoula
country: United States
facility: Forest Investigative Site 1400
state: Montana
city: Bellevue
country: United States
facility: Forest Investigative Site 1609
state: Nebraska
city: Fremont
country: United States
facility: Forest Investigative Site 1948
state: Nebraska
city: Lincoln
country: United States
facility: Forest Investigative Site 1815
state: Nebraska
city: Omaha
country: United States
facility: Forest Investigative Site 1363
state: Nebraska
city: Omaha
country: United States
facility: Forest Investigative Site 1907
state: Nebraska
city: Omaha
country: United States
facility: Forest Investigative Site 1911
state: Nebraska
city: Omaha
country: United States
facility: Forest Investigative Site 1908
state: Nebraska
city: Omaha
country: United States
facility: Forest Investigative Site 1804
state: Nebraska
city: Henderson
country: United States
facility: Forest Investigative Site 1807
state: Nevada
city: Las Vegas
country: United States
facility: Forest Investigative Site 1834
state: Nevada
city: Las Vegas
country: United States
facility: Forest Investigative Site 1562
state: Nevada
city: Cherry Hill
country: United States
facility: Forest Investigative Site 1559
state: New Jersey
city: Hackensack
country: United States
facility: Forest Investigative Site 1923
state: New Jersey
city: Albuquerque
country: United States
facility: Forest Investigative Site 1949
state: New Mexico
city: Great Neck
country: United States
facility: Forest Investigative Site 1151
state: New York
city: Larchmont
country: United States
facility: Forest Investigative Site 1489
state: New York
city: New York
country: United States
facility: Forest Investigative Site 0550
state: New York
city: New York
country: United States
facility: Forest Investigative Site 1425
state: New York
city: Rochester
country: United States
facility: Forest Investigative Site 2098
state: New York
city: Charlotte
country: United States
facility: Forest Investigative Site 1392
state: North Carolina
city: Elizabeth City
country: United States
facility: Forest Investigative Site 2035
state: North Carolina
city: High Point
country: United States
facility: Forest Investigative Site 1366
state: North Carolina
city: Raleigh
country: United States
facility: Forest Investigative Site 1153
state: North Carolina
city: Salisbury
country: United States
facility: Forest Investigative Site 1823
state: North Carolina
city: Cadiz
country: United States
facility: Forest Investigative Site 1891
state: Ohio
city: Canton
country: United States
facility: Forest Investigative Site 1134
state: Ohio
city: Cincinnati
country: United States
facility: Forest Investigative Site 1885
state: Ohio
city: Cincinnati
country: United States
facility: Forest Investigative Site 1806
state: Ohio
city: Cincinnati
country: United States
facility: Forest Investigative Site 2028
state: Ohio
city: Cincinnati
country: United States
facility: Forest Investigative Site 1903
state: Ohio
city: Columbus
country: United States
facility: Forest Investigative Site 1361
state: Ohio
city: Columbus
country: United States
facility: Forest Investigative Site 1433
state: Ohio
city: Sylvania
country: United States
facility: Forest Investigative Site 2090
state: Ohio
city: Toledo
country: United States
facility: Forest Investigative Site 1530
state: Ohio
city: Zanesville
country: United States
facility: Forest Investigative Site 1393
state: Ohio
city: Oklahoma City
country: United States
facility: Forest Investigative Site 1915
state: Oklahoma
city: Bend
country: United States
facility: Forest Investigative Site 1889
state: Oregon
city: Medford
country: United States
facility: Forest Investigative Site 2043
state: Oregon
city: Altoona
country: United States
facility: Forest Investigative Site 1833
state: Pennsylvania
city: Clairton
country: United States
facility: Forest Investigative Site 1855
state: Pennsylvania
city: Downington
country: United States
facility: Forest Investigative Site 1820
state: Pennsylvania
city: Erie
country: United States
facility: Forest Investigative Site 1423
state: Pennsylvania
city: Langhorne
country: United States
facility: Forest Investigative Site 1899
state: Pennsylvania
city: Philadelphia
country: United States
facility: Forest Investigative Site 1443
state: Pennsylvania
city: Phoenixville
country: United States
facility: Forest Investigative Site 1863
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Forest Investigative Site 1146
state: Pennsylvania
city: Tipton
country: United States
facility: Forest Investigative Site 1449
state: Pennsylvania
city: Uniontown
country: United States
facility: Forest Investigative Site 1862
state: Pennsylvania
city: Cumberland
country: United States
facility: Forest Investigative Site 1832
state: Rhode Island
city: East Providence
country: United States
facility: Forest Investigative Site 1089
state: Rhode Island
city: Charleston
country: United States
facility: Forest Investigative Site 2072
state: South Carolina
city: Charleston
country: United States
facility: Forest Investigative Site 1905
state: South Carolina
city: Charleston
country: United States
facility: Forest Investigative Site 1802
state: South Carolina
city: Fort Mill
country: United States
facility: Forest Investigative Site 1914
state: South Carolina
city: Gaffney
country: United States
facility: Forest Investigative Site 1913
state: South Carolina
city: Spartanburg
country: United States
facility: Forest Investigative Site 1121
state: South Carolina
city: Brentwood
country: United States
facility: Forest Investigative Site 1957
state: Tennessee
city: Fayetteville
country: United States
facility: Forest Investigative Site 1526
state: Tennessee
city: Arlington
country: United States
facility: Forest Investigative Site 1440
state: Texas
city: Boerne
country: United States
facility: Forest Investigative Site 1879
state: Texas
city: Carrollton
country: United States
facility: Forest Investigative Site 1861
state: Texas
city: Corsicana
country: United States
facility: Forest Investigative Site 1816
state: Texas
city: Dallas
country: United States
facility: Forest Investigative Site 1890
state: Texas
city: El Paso
country: United States
facility: Forest Investigative Site 1332
state: Texas
city: Fort Worth
country: United States
facility: Forest Investigative Site 2012
state: Texas
city: Houston
country: United States
facility: Forest Investigative Site 1951
state: Texas
city: Killeen
country: United States
facility: Forest Investigative Site 1902
state: Texas
city: Mckinney
country: United States
facility: Forest Investigative Site 1091
state: Texas
city: Plano
country: United States
facility: Forest Investigative Site 1826
state: Texas
city: San Angelo
country: United States
facility: Forest Investigative Site 0526
state: Texas
city: San Antonio
country: United States
facility: Forest Investigative Site 1895
state: Texas
city: Salt Lake City
country: United States
facility: Forest Investigative Site 1936
state: Utah
city: South Burlington
country: United States
facility: Forest Investigative Site 1330
state: Vermont
city: Newport News
country: United States
facility: Forest Investigative Site 1945
state: Virginia
city: Norfolk
country: United States
facility: Forest Investigative Site 1404
state: Virginia
city: Bellingham
country: United States
facility: Forest Investigative Site 1120
state: Washington
city: Spokane
country: United States
facility: Forest Investigative Site 1977
state: Washington
city: Spokane
country: United States
facility: Forest Investigative Site 1878
state: Washington
city: Spokane
country: United States
facility: Forest Investigative Site 1573
state: Washington
city: Tacoma
country: United States
facility: Forest Investigative Site 0988
state: Washington
city: Tacoma
country: United States
facility: Forest Investigative Site 1870
state: Washington
city: Morgantown
country: United States
facility: Forest Investigative Site 1555
state: West Virginia
city: New Lambton
country: Australia
facility: Forest Investigative Site 1991
state: New South Wales
city: Redcliffe
country: Australia
facility: Forest Investigative Site 1987
state: Queensland
city: Woolloongabba
country: Australia
facility: Forest Investigative Site 1973
state: Queensland
city: Bedford Park
country: Australia
facility: Forest Investigative Site 1981
state: South Australia
city: Daw Park
country: Australia
facility: Forest Investigative Site 1990
state: South Australia
city: Toorak Gardens
country: Australia
facility: Forest Investigative Site 2251
state: South Australia
city: Clayton
country: Australia
facility: Forest Investigative Site 2250
state: Victoria
city: Fitzroy
country: Australia
facility: Forest Investigative Site 1972
state: Victoria
city: Geelong
country: Australia
facility: Forest Investigative Site 1986
state: Victoria
city: Parkville
country: Australia
facility: Forest Investigative Site 1985
state: Victoria
city: Adelaide
country: Australia
facility: Forest Investigative Site 2253
state: Western Australia
city: Langley
country: Canada
facility: Forest Investigative Site 1904
state: British Columbia
city: Vancouver
country: Canada
facility: Forest Investigative Site 0905
state: British Columbia
city: Winnipeg
country: Canada
facility: Forest Investigative Site 0976
state: Manitoba
city: Sarina
country: Canada
facility: Forest Investigative Site 1877
state: Ontario
city: Sarnia
country: Canada
facility: Forest Investigative Site 1896
state: Ontario
city: Toronto
country: Canada
facility: Forest Investigative Site 1171
state: Ontario
city: Toronto
country: Canada
facility: Forest Investigative Site 2203
state: Ontario
city: Montreal
country: Canada
facility: Forest Investigative Site 1952
state: Quebec
city: Saskatoon
country: Canada
facility: Forest Investigative Site 0943
state: Saskatchewan
city: Quebec
country: Canada
facility: Forest Investigative Site 1859
city: Auckland
country: New Zealand
facility: Forest Investigative Site 1027
city: Christchurch
country: New Zealand
facility: Forest Investigative Site 1970
city: Dunedin
country: New Zealand
facility: Forest Investigative Site 1967
city: Dunedin
country: New Zealand
facility: Forest Investigative Site 1964
city: Hamilton
country: New Zealand
facility: Forest Investigative Site 1968
city: Tauranga
country: New Zealand
facility: Forest Investigative Site 1965
city: Tauranga
country: New Zealand
facility: Forest Investigative Site 1980
city: Wellington
country: New Zealand
facility: Forest Investigative Site 1025
Study officials:
affiliation: AstraZeneca
name: Esther Garcia, MD
role: STUDY_DIRECTOR
References:
citation: Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naive Patients With COPD. Int J Chron Obstruct Pulmon Dis. 2019 Dec 6;14:2835-2848. doi: 10.2147/COPD.S217710. eCollection 2019.
citation: Singh D, D'Urzo AD, Chuecos F, Munoz A, Garcia Gil E. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017 May 30;18(1):106. doi: 10.1186/s12931-017-0583-0.
citation: Jones PW, Leidy NK, Hareendran A, Lamarca R, Chuecos F, Garcia Gil E. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016 May 23;17(1):61. doi: 10.1186/s12931-016-0372-1.
citation: Bateman ED, Chapman KR, Singh D, D'Urzo AD, Molins E, Leselbaum A, Gil EG. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015 Aug 2;16(1):92. doi: 10.1186/s12931-015-0250-2.
citation: D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF; AUGMENT COPD study investigators. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014 Oct 14;15(1):123. doi: 10.1186/s12931-014-0123-0.